Novel Germline BRCA1 and BRCA2 Mutations in Turkish Women with Breast and/or Ovarian Cancer and Their Relatives

REFERENCES

• Turkish Ministry of Health. Republic of Turkey health statistics, Turkish Ministry of Health. 1999, Online: www.saglik.gov.tr/istatistikler
   Google Scholar
• Szabo C. I., King M. C. Population genetics of BRCA1 and BRCA2. Am. J. Hum. Genet. 1997; 60: 1013–1020, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Abeliouich D., Kaduri L., Lerer I., Weinberg N., Amir G., et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am. J. Hum. Genet. 1997; 60: 505–514, [CSA]
   PubMed Web of Science ®Google Scholar
• Leavy-Lahad E., Catane R., Eisenberg S., Kaufman B., Hornreich G., et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am. J. Hum. Genet. 1997; 60(5)1059–1067, [CSA]
   PubMed Web of Science ®Google Scholar
• Tryggvadottir L., Olafsdottir E. J., Gudlaugsdottir S., Thorlacius S., Jonasson J. G., et al. BRCA2 mutation cariers, reproductive factors and breast cancer risk. Breast Cancer Res. 2003; 5(5)121–128, [CSA], [CROSSREF]
   Google Scholar
• Balci A., Huusko P., Pakkonen K., Launonen V., Uner A., et al. Mutational analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3424del4 found in male breast cancer. Eur. J. Cancer 1999; 35: 707–710, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ozdag H., Tez M., Sayek I., Muslumanoglu M., Tarcan O., et al. Germline BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients. Eur. J. Cancer 2000; 36: 2076–2082, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yazici H., Bitisik O., Akisik E., Cabioglu N., Saip P., et al. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br. J. Cancer 2000; 83: 737–742, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Manguoglu A. E., Luleci G., Ozcelik T., Colak T., Schayek H., et al. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients. Hum. Mutat. 2003; 21(4)444–445, Mutation in Brief #590[INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Yazici H., Glendon G., Yazici H., Burnie S. J., Saip P., et al. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Hum. Mutat. 2002; 20: 28–34, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Friedman L. S., Gayter S. A., Kurosaki T. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am. J. Hum. Genet. 1997; 60: 313–319, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tavtigian S. V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 1996; 12: 333–337, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hakansson S., Johannsson O., Johannsson U., Sellberg G., Loman N., Gerdes A. M. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am. J. Hum. Genet. 1997; 60(5)1068–1078, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sanger F., Nicklen S., Caulson A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 1977; 74: 463–467, [CSA], [CROSSREF]
   Google Scholar
• Martinez-Ferrandis J. I., Vega A., Chirivella I., Marin–Garcia P., Insa A., et al. Mutational analysis of BRCA1 and BRCA2 in Mediterrranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations. Hum. Mutat. 2003; 22(5)417–418, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Hamann U., Liu X., Bungardt N., Ulmer H. U., Bastert G., Sinn H. P. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany. Eur. J. Hum. Genet. 2003; 11(6)464–467, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Sanjose S., Leone M., Berez V., Izquierdo A., Font R., Brunet J. M., Louat T., Vilardell L., Borras J., Viladiu P., Bosch F. X., Lenoir G. M., Sinilnikova O. M. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J. Cancer. 2003; 106(4)588–593, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Loman N., Bladstrom A., Johannsson O., Borg A., Olsson H. Cncer incidence in relatives of a population-based set of cases early-onset breast cancer with a known BRCA1 and BRCA2 mutations status. Breast Cancer Res. Aug, 2003; 5(6)175–186, [CSA], [CROSSREF]
   Google Scholar
• Berry D. A., Iversen E S, Jr., Gudbjartsson D. F., Hiller E. H., Garber J. E., Peshkin B. N., Lerman V., Watson P., Lynch H. A.T., Hilsenbeck S. G., Rubinsten W. S., Hughes K. S., Parmigiani G. BRCAPRO validation. Sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J. Clin. Oncol. 2002; 20: 2701–2712, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Futreal P. A., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., Bennett L. M., Haugen-Strano A., Swensen J., Miki Y. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266: 120–122, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–792, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ladopoulou A., Kroupis C., Konstantopoulou I., Ioannidou-Mouzaka L., Schofield A. C., Pantazidis A., Armaou S., Tsiagas I., Lianidou E., Efstathiou E., Tsionou C., Panopoulos C., Mihalatos M., Nasioulas G., Skarlos D., Haites N. E., Fountzilas G., Pandis N., Yannoukakos D. Germline BRCA1&BRCA2 mutations in Grek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Letters 2002; 185: 61–70, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Neuhausen SL. Ethnic differences in cancer risk resulting from genetic variation. Cancer 1999; 86: 2575–2582, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Osorio A., Barroso A., Martinez B., Cebrian A., San Roman J. M., Lobo F., Robledo M., Benitez J. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br. J. Cancer 2000; 82: 1266–1270, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goolen G., Teugels E., Bonduelle M., Neyns B., De Greve J. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. J. Med. Genet. 1999; 36: 304–308, [CSA]
   PubMed Web of Science ®Google Scholar
• Stuppia L., Di Fulvio P., Aceto G., Pintor S., Veschi S., Gatta V., Colosimo A., Cianchetti E., Cama A., Mariani-Constantini R., Battista P., Palka G. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy. Hum. Mutat. Aug, 2003; 22(2)178–179, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Meindl A. German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int. J. Cancer Feb 1, 2002; 97(4)472–480, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Verhoog L. C., van den Ouweland A. M., Berns E., van Veghel-Plandsoen M. M., van Staveren I. L., Wagner A., Bartells C. C., Tilanus-Linthorst M. M., Devilee P., Seynaeve C., Halley D. J., Niermeijer M. F., Klinj J. G., Meijers-Heijboer H. Large regional differences in the frequency of distict BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur. J. Cancer Nov, 2001; 37(16)2082–2090, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vehmanen P., Friedman L. S., Eurola H., McClure M., Ward B., Sarantha L., Kainu T., Syrjakoski K., Pyrhonen S., Kallioniemi O. P., Muhonen T., Luce M., Frank T. S., Nevanlinna H. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum. Mol. Genet. 1997; 6(13)2309–2315, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ghaderi A., Talei A., Farjadian S., Mosalaei A., Doroudchi M., Kimura H. Germline BRCA1 mutations in Iranian women with breast cancer. Cancer Letters 2001; 165: 87–94, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Saxena S., Szabo C. I., Chopin S., Barjhoux L., Sinilnikova O., Lenoir G., Goldgar D. E., Bhataneger D. BRCA1 and BRCA2 in Indian breast cancer patients. Hum. Mutat. 2002, Mutation in Brief#553 Online[CSA]
   PubMedGoogle Scholar
• Xiangcheng Z., Szabo C., Chopin S., Suter N., Wang Q.-S., Ostrander E. A., Sinilnikova O. M., Lenoir G. M., Goldgar D., Shi Y.-R. BRCA1 and BRCA2 sequence variants in Chinese breast cancer families. Hum. Mutat. 2002, Mutation in Brief#554 Online[CSA]
   Google Scholar
• Teng D. H., Bogden R., Mitchell J., Baumgard M., Bell R., Berry S., Davis T., Ha P. C., Kehrer R., Jammulapati S., Chen Q., Offit K., Skolnick M. H., Tavtigian S. V., Jhanwar S., Swedlund B., Wong A. K., Kamb A. Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat. Genet. June, 1996; 13(2)241–244, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wagner T. M., Hirtenlehner K., Shen P., Moeslinger R., Muhr D., Fleischmann E., Concin H., Doeller W., Haid A., Lang A. H., Mayer P., Petru E., Ropp E., Langbauer G., Kubista E., Scheiner O., Underhill P., Mountain J., Stierer M., Zielinski C., Oefner P. Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum. Mol. Genet. Mar, 1999; 8(3)413–423, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dunning A. M., Chiano M., Smith N. R., Dearden J., Gore M., Oakes S., Wilson C., Stratton M., Peto J., Easton D., Clayton D., Ponder B. A. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum. Mol. Genet. Feb, 1997; 6(2)285–289, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goode E. L., Ulrich C. M., Potter J. D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 2002; 11(12)1513–1530, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ishitobi M., Miyoshi Y., Ando A., Hasegawa S., Egawa C., Tamaki Y., Monden M., Noguchi S. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Clin. Cancer Res. 2003; 9(4)1376–1380, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wenham R. M., Schildkraut J. M., McLean K., Calingaert B., Bentley R. C., Marks J., Berchuck A. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin. Cancer Res. 2003; 9(12)4396–4403, 1[INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Spurdle A. B., Hopper J. L., Chen X., Dite G. S., Cui J., McCredie M. R., Giles G. G., Ellis-Steinborder S., Venter D. J., Newman B., Southey M. C., Chenevix-Trench G. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol. Biomarkers Prev. 2002; 11(4)413–416, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Auranen A., Spurdle A. B., Chen X., Lipscombe J., Purdie D. M., Hopper J. L., Gren A., Healey C. S., Redman K., Dunning A. M., Pharoah P. D., Easton D. F., Ponder B. A., Chenevix-Trench G., Novik K. L. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int. J. Cancer 2003; 103(3)427–430, 20[INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Liu H X., Cartegni L., Zhang M Q., Krainer A R. A mechanismfor exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat. Genet. Jan, 2001; 27(1)55–58, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moslei R., Russo D., Phelan C., Jack E., Antman K., Narod S. An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2. Clin. Genet. 2000; 57: 70–73, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hartge P., Struewing J. P., Wacholder S., Brody L. C., Tucker M. A. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am. J. Hum. Genet. 1999; 64: 963–970, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Warner E., Foulnes W., Goodwin P., Meschino W., Blondal J., Paterson C., Ozcelik H., Goss P., Allingham-Hawkins D., Hamel N., Di Prospero L., Contiga V., Serruya C., Klein M., Moslehi R., Honeyford J., Liede A., Glendon G., Brunet J. S., Narod S. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J. Natl. Cancer Inst. 1999; 91: 1241–1247, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Modan B., Hartge P., Hirsh-Yechezhel G., Chetrit A., Lubin F., Beller U., Ben-Baruch G., Fishman A., Menczer J., Ebbers S. M., Tucker M. A., Wacholder S., Struewing J. P., Friedman E., Piura B. Parity, oral contraseptives, and the risk of ovarian cancer among carriers of a BRCA1 and BRCA2 mutation. N. Eng. J. Med. 2001; 345: 235–240, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Apicella C., Andrews L., Hodgson S. V., Fisher S. A., Lewis C. M., Solomon E., Tucker K., Friedlander M., Bankier A., Southey M. C., Venter D. J., Hopper J. L. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res. 2003; 5(6)206–216, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Arason A., Jonasdottir A., Barkardottir R. B., Bergthorsson J. T., Teare M. D., Easton D. F., Egilsson V. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J. Med. Genet. June, 1998; 35(6)446–449, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Huusko P., Paakkonen K., Launonen V., Poyhonen M., Blanco G., Kauppila A., Puistola U., Kiviniemi H., Kujala M., Leisti J., Winqvist R. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am. J. Hum. Genet. Jun, 1998; 62(6)1544–1548, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Peelen T., van Vliet M., Petrij-Bosch A., Mieremet R., Szabo C., van den Ouweland A. M., Hogervorst F., Brohet R., Ligtenberg M. J., Teugels E., van der Luijt R., van der Hout A. H., Gille J. J., Pals G., Jedema I., Olmer R., van Leeuwen I., Newman B., Plandsoen M., van der Est M., Brink G., Hageman S., Arts P. J., Bakker M. M., Devilee P. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am. J. Hum. Genet. May, 1997; 60(5)1041–1049, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar